| Literature DB >> 15194037 |
Guy Amit1, Amit Rosen, Avraham B Wagshal, Dan Y Bonneh, Tzvika Liss, Aviva Grosbard, Reuven Ilia, Amos Katz.
Abstract
The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15194037 DOI： 10.1016/j.amjcard.2004.02.071
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778